Hap Trading, LLC Exelixis, Inc. Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $248,055 - $310,939	12,886 New	12,886 $309 Million
Q3 2021 Nov 10, 2021	BUY	$16.3 - $21.14 $55,599 - $72,108	3,411 Added 25.3%	16,895 $357,000
Q2 2021 Aug 11, 2021	BUY	$17.95 - $25.56 $25,255 - $35,962	1,407 Added 11.65%	13,484 $246,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $40,054 - $49,204	-1,951 Reduced 13.91%	12,077 $273,000
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $772 - $1,041	42 Added 0.3%	14,028 $282,000
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $164,285 - $214,119	-7,948 Reduced 36.24%	13,986 $342,000
Q1 2020 May 08, 2020	SELL	$14.46 - $21.8 $67,051 - $101,086	-4,637 Reduced 17.45%	21,934 $378,000
Q3 2019 Nov 12, 2019	BUY	$17.68 - $22.65 $469,775 - $601,833	26,571 New	26,571 $470,000
Q2 2018 Aug 13, 2018	SELL	$18.56 - $22.45 $831,135 - $1.01 Million	-44,781 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $991,899 - $1.43 Million	44,781 New	44,781 $992,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.